FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3002510199> ?p ?o ?g. }

• W3002510199 endingPage "1763" @default.
• W3002510199 startingPage "1755" @default.
• W3002510199 abstract "Background Anxiety and depression are common among psoriasis and psoriatic arthritis (PsA) patients, but rates may differ by treatment. Objective To quantify the risk of incident treated anxiety, depression and mixed anxiety + depression in users of apremilast compared with users of other treatments for psoriasis and PsA. Methods We conducted two separate cohort studies of psoriasis and PsA patients treated with apremilast, tumour necrosis factor inhibitor biologics, interleukin-17, -23 or -12/23 inhibitor biologics, conventional DMARDs or systemic corticosteroids in the United States MarketScan database. Cohort entry was date of first study drug after 21 March 2014. We identified cases who had a depression and/or anxiety diagnosis with a prescription for antidepressant/antianxiety medication within 30 days of the diagnosis code. We calculated incidence rates (IRs) and incidence rate ratios with 95% confidence intervals (CIs) for treated anxiety, treated depression and treated anxiety + depression per 1000 patient-years (PY) among patients. Results Among the psoriasis cohort, IRs for each outcome were similar between exposure categories and highest among users of systemic corticosteroids alone. IRs (95% CI) for apremilast alone were 9.2 (6.6-12.5), 4.6 (2.8-7.1) and 4.6 (2.8-7.1) per 1000 PY for treated anxiety, treated depression and treated anxiety + depression, respectively. In the PsA cohort, the rate of anxiety was highest among users of apremilast alone; rates of depression and anxiety + depression were similar for apremilast compared with other PsA treatments. IRs for each outcome were also high for users of corticosteroids in both the psoriasis and PsA cohorts. Conclusions Among patients with psoriasis, users of apremilast had similar rates of anxiety and depression as users of other non-corticosteroid systemic psoriasis treatments. Among PsA patients, users of apremilast had similar rates of depression and anxiety + depression compared with users of other systemic non-corticosteroid PsA drugs; however, the rate of anxiety was slightly higher." @default.
• W3002510199 created "2020-01-30" @default.
• W3002510199 creator A5025121087 @default.
• W3002510199 creator A5047458854 @default.
• W3002510199 creator A5054295964 @default.
• W3002510199 creator A5066275631 @default.
• W3002510199 date "2020-02-28" @default.
• W3002510199 modified "2023-10-13" @default.
• W3002510199 title "The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database" @default.
• W3002510199 cites W1969688844 @default.
• W3002510199 cites W1973403477 @default.
• W3002510199 cites W2005241673 @default.
• W3002510199 cites W2038934200 @default.
• W3002510199 cites W2519503335 @default.
• W3002510199 cites W2606731929 @default.
• W3002510199 cites W2616032193 @default.
• W3002510199 cites W2754104556 @default.
• W3002510199 cites W2891708136 @default.
• W3002510199 cites W2907171532 @default.
• W3002510199 cites W2914164523 @default.
• W3002510199 cites W2947263714 @default.
• W3002510199 doi "https://doi.org/10.1111/jdv.16231" @default.
• W3002510199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31981426" @default.
• W3002510199 hasPublicationYear "2020" @default.
• W3002510199 type Work @default.
• W3002510199 sameAs 3002510199 @default.
• W3002510199 citedByCount "10" @default.
• W3002510199 countsByYear W30025101992021 @default.
• W3002510199 countsByYear W30025101992022 @default.
• W3002510199 countsByYear W30025101992023 @default.
• W3002510199 crossrefType "journal-article" @default.
• W3002510199 hasAuthorship W3002510199A5025121087 @default.
• W3002510199 hasAuthorship W3002510199A5047458854 @default.
• W3002510199 hasAuthorship W3002510199A5054295964 @default.
• W3002510199 hasAuthorship W3002510199A5066275631 @default.
• W3002510199 hasConcept C118552586 @default.
• W3002510199 hasConcept C126322002 @default.
• W3002510199 hasConcept C139719470 @default.
• W3002510199 hasConcept C16005928 @default.
• W3002510199 hasConcept C162324750 @default.
• W3002510199 hasConcept C2776260265 @default.
• W3002510199 hasConcept C2776867660 @default.
• W3002510199 hasConcept C2780564577 @default.
• W3002510199 hasConcept C2781059491 @default.
• W3002510199 hasConcept C2781427535 @default.
• W3002510199 hasConcept C558461103 @default.
• W3002510199 hasConcept C71924100 @default.
• W3002510199 hasConcept C72563966 @default.
• W3002510199 hasConceptScore W3002510199C118552586 @default.
• W3002510199 hasConceptScore W3002510199C126322002 @default.
• W3002510199 hasConceptScore W3002510199C139719470 @default.
• W3002510199 hasConceptScore W3002510199C16005928 @default.
• W3002510199 hasConceptScore W3002510199C162324750 @default.
• W3002510199 hasConceptScore W3002510199C2776260265 @default.
• W3002510199 hasConceptScore W3002510199C2776867660 @default.
• W3002510199 hasConceptScore W3002510199C2780564577 @default.
• W3002510199 hasConceptScore W3002510199C2781059491 @default.
• W3002510199 hasConceptScore W3002510199C2781427535 @default.
• W3002510199 hasConceptScore W3002510199C558461103 @default.
• W3002510199 hasConceptScore W3002510199C71924100 @default.
• W3002510199 hasConceptScore W3002510199C72563966 @default.
• W3002510199 hasFunder F4320309086 @default.
• W3002510199 hasIssue "8" @default.
• W3002510199 hasLocation W30025101991 @default.
• W3002510199 hasOpenAccess W3002510199 @default.
• W3002510199 hasPrimaryLocation W30025101991 @default.
• W3002510199 hasRelatedWork W2313199171 @default.
• W3002510199 hasRelatedWork W2402155348 @default.
• W3002510199 hasRelatedWork W2790463647 @default.
• W3002510199 hasRelatedWork W2891943640 @default.
• W3002510199 hasRelatedWork W2991200093 @default.
• W3002510199 hasRelatedWork W3108657795 @default.
• W3002510199 hasRelatedWork W3195838575 @default.
• W3002510199 hasRelatedWork W3200801096 @default.
• W3002510199 hasRelatedWork W4200567964 @default.
• W3002510199 hasRelatedWork W4246299568 @default.
• W3002510199 hasVolume "34" @default.
• W3002510199 isParatext "false" @default.
• W3002510199 isRetracted "false" @default.
• W3002510199 magId "3002510199" @default.
• W3002510199 workType "article" @default.